TSC is characterized primarily by non-malignant tumors in multiple organ systems as a result of mutations in TSC1 (hamartin) or TSC2 (tuberin), which normally combine to downregulate mTOR signaling related cell growth and proliferation [3, 4]. Here, TSC1 is linked to tuberous sclerosis.